Evidence map›Paper›PMID 35729224›Full record

ArticleScientific reports2022

Using fluorescent promoter-reporters to study sugar utilization control in Bifidobacterium longum NCC 2705.

S Duboux, J A Muller, F De Franceschi, A Mercenier, M Kleerebezem

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Proteomic Analysis ofFoods (Basel, Switzerland) · 2025
    Article
  3. The gut microbiota and its biogeography.Nature reviews. Microbiology · 2024
    Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

S DubouxNestlé Research, Lausanne, Switzerland. stephane.duboux@rdls.nestle.com.
J A MullerNestlé Research, Lausanne, Switzerland.
F De FranceschiNestlé Research, Lausanne, Switzerland.
A MercenierHost-Microbe Interactomics Group, Wageningen University and Research, De Elst 1, 6708WD, Wageningen, The Netherlands.
M KleerebezemHost-Microbe Interactomics Group, Wageningen University and Research, De Elst 1, 6708WD, Wageningen, The Netherlands. michiel.kleerebezem@wur.nl.
Nestlé (Switzerland) · CHWageningen University & Research · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bifidobacteria are amongst the first bacteria to colonize the human gastro-intestinal system and have been proposed to play a crucial role in the development of the infant gut since their absence is correlated to the development of diseases later in life. Bifidobacteria have the capacity to metabolize a diverse range of (complex) carbohydrates, reflecting their adaptation to the lower gastro-intestinal tract. Detailed understanding of carbohydrate metabolism regulation in this genus is of prime importance and availability of additional genetic tools easing such studies would be beneficial. To develop a fluorescent protein-based reporter system that can be used in B. longum NCC 2705, we first selected the most promising fluorescent protein out of the seven we tested (i.e., mCherry). This reporter protein was then used to study the carbohydrate mediated activation of P

Indexed as

Bifidobacterium longumArabinoseBifidobacteriumCarbohydratesGalactoseGlucoseHumansInfantArabinoseCarbohydratesGalactoseGlucose

Identifiers

PMID35729224
PMCPMC9213400
OpenAlexW4283271823

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.